Under the terms of the agreement, Grunenthal will supply Obecure with betahistine and matching placebo tablets for use in its upcoming clinical studies. Pending successful development and receipt of a marketing authorization of Histalean (betahistine) in Europe, Grunenthal will exclusively supply the betahistine tablets for packaging as Histalean for all countries in European Community. Grunenthal will also be entitled to license Histalean for co-marketing in Italy.
Yaffa Beck, CEO of Obecure, said: “This agreement is a major step forward in the development of Histalean for Obesity and weight management and to ensure its availability to patients upon approval. The Grunenthal Group is a leader in the European pharmaceutical industry and provides Obecure access to large scale production and marketing organization and the capacity to meet production and quality goals.”